The regulation of insulin and glucagon secretion by opiates

A study with naloxone in healthy humans

Alessandro Locatelli, Donatella Spotti, Francesco Caviezel

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The presence of β-endorphin and enkephalin in pancreatic islets suggests that opioid peptides may play a role in the regulation of pancreatic endocrine function. Since data in the literature are rather controversial, we examined the effects of different doses of naloxone on insulin and glucagon secretion in 21 healthy nonobese volunteers (6 women and 15 men) by measuring the variations of insulin and glucagon plasma levels following a 5-g i.v. glucose load before and during a 30-min naloxone infusion. Total amounts of 0.4 and 0.8 mg of naloxone failed to modify serum insulin and plasma glucose responses to glucose challenge. On the contrary, 0.2 mg/kg (i.e. 12-14 mg per subject as total amount) given to 3 women and 6 men led to a glucose-induced insulin release significantly lower than that recorded in basal conditions, with corresponding greater plasma glucose elevation. The suppressive effect of glucose on glucagon concentration was less pronounced during naloxone. Data reported here suggest that inhibition of opiate receptors in human pancreas occurs only with large amounts of naloxone. Moreover, they may indirectly support the stimulatory role of opioid peptides on insulin secretion in man, according to some experimental in vitro and in vivo studies. In addition, naloxone seems to reduce pancreatic A-cell sensitivity to hyperglycemia.

Original languageEnglish
Pages (from-to)25-31
Number of pages7
JournalActa Diabetologica Latina
Volume22
Issue number1
DOIs
Publication statusPublished - Jan 1985

Fingerprint

Opiate Alkaloids
Naloxone
Glucagon
Insulin
Glucose
Opioid Peptides
Glucagon-Secreting Cells
Endorphins
Enkephalins
Opioid Receptors
Islets of Langerhans
Hyperglycemia
Pancreas
Healthy Volunteers

Keywords

  • Endorphin
  • Glucagon
  • Insulin
  • Nalcxone

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

The regulation of insulin and glucagon secretion by opiates : A study with naloxone in healthy humans. / Locatelli, Alessandro; Spotti, Donatella; Caviezel, Francesco.

In: Acta Diabetologica Latina, Vol. 22, No. 1, 01.1985, p. 25-31.

Research output: Contribution to journalArticle

Locatelli, Alessandro ; Spotti, Donatella ; Caviezel, Francesco. / The regulation of insulin and glucagon secretion by opiates : A study with naloxone in healthy humans. In: Acta Diabetologica Latina. 1985 ; Vol. 22, No. 1. pp. 25-31.
@article{3da22711ccf44583ae21ff50d64969d7,
title = "The regulation of insulin and glucagon secretion by opiates: A study with naloxone in healthy humans",
abstract = "The presence of β-endorphin and enkephalin in pancreatic islets suggests that opioid peptides may play a role in the regulation of pancreatic endocrine function. Since data in the literature are rather controversial, we examined the effects of different doses of naloxone on insulin and glucagon secretion in 21 healthy nonobese volunteers (6 women and 15 men) by measuring the variations of insulin and glucagon plasma levels following a 5-g i.v. glucose load before and during a 30-min naloxone infusion. Total amounts of 0.4 and 0.8 mg of naloxone failed to modify serum insulin and plasma glucose responses to glucose challenge. On the contrary, 0.2 mg/kg (i.e. 12-14 mg per subject as total amount) given to 3 women and 6 men led to a glucose-induced insulin release significantly lower than that recorded in basal conditions, with corresponding greater plasma glucose elevation. The suppressive effect of glucose on glucagon concentration was less pronounced during naloxone. Data reported here suggest that inhibition of opiate receptors in human pancreas occurs only with large amounts of naloxone. Moreover, they may indirectly support the stimulatory role of opioid peptides on insulin secretion in man, according to some experimental in vitro and in vivo studies. In addition, naloxone seems to reduce pancreatic A-cell sensitivity to hyperglycemia.",
keywords = "Endorphin, Glucagon, Insulin, Nalcxone",
author = "Alessandro Locatelli and Donatella Spotti and Francesco Caviezel",
year = "1985",
month = "1",
doi = "10.1007/BF02591089",
language = "English",
volume = "22",
pages = "25--31",
journal = "Acta Diabetologica",
issn = "0940-5429",
publisher = "Springer-Verlag Italia s.r.l.",
number = "1",

}

TY - JOUR

T1 - The regulation of insulin and glucagon secretion by opiates

T2 - A study with naloxone in healthy humans

AU - Locatelli, Alessandro

AU - Spotti, Donatella

AU - Caviezel, Francesco

PY - 1985/1

Y1 - 1985/1

N2 - The presence of β-endorphin and enkephalin in pancreatic islets suggests that opioid peptides may play a role in the regulation of pancreatic endocrine function. Since data in the literature are rather controversial, we examined the effects of different doses of naloxone on insulin and glucagon secretion in 21 healthy nonobese volunteers (6 women and 15 men) by measuring the variations of insulin and glucagon plasma levels following a 5-g i.v. glucose load before and during a 30-min naloxone infusion. Total amounts of 0.4 and 0.8 mg of naloxone failed to modify serum insulin and plasma glucose responses to glucose challenge. On the contrary, 0.2 mg/kg (i.e. 12-14 mg per subject as total amount) given to 3 women and 6 men led to a glucose-induced insulin release significantly lower than that recorded in basal conditions, with corresponding greater plasma glucose elevation. The suppressive effect of glucose on glucagon concentration was less pronounced during naloxone. Data reported here suggest that inhibition of opiate receptors in human pancreas occurs only with large amounts of naloxone. Moreover, they may indirectly support the stimulatory role of opioid peptides on insulin secretion in man, according to some experimental in vitro and in vivo studies. In addition, naloxone seems to reduce pancreatic A-cell sensitivity to hyperglycemia.

AB - The presence of β-endorphin and enkephalin in pancreatic islets suggests that opioid peptides may play a role in the regulation of pancreatic endocrine function. Since data in the literature are rather controversial, we examined the effects of different doses of naloxone on insulin and glucagon secretion in 21 healthy nonobese volunteers (6 women and 15 men) by measuring the variations of insulin and glucagon plasma levels following a 5-g i.v. glucose load before and during a 30-min naloxone infusion. Total amounts of 0.4 and 0.8 mg of naloxone failed to modify serum insulin and plasma glucose responses to glucose challenge. On the contrary, 0.2 mg/kg (i.e. 12-14 mg per subject as total amount) given to 3 women and 6 men led to a glucose-induced insulin release significantly lower than that recorded in basal conditions, with corresponding greater plasma glucose elevation. The suppressive effect of glucose on glucagon concentration was less pronounced during naloxone. Data reported here suggest that inhibition of opiate receptors in human pancreas occurs only with large amounts of naloxone. Moreover, they may indirectly support the stimulatory role of opioid peptides on insulin secretion in man, according to some experimental in vitro and in vivo studies. In addition, naloxone seems to reduce pancreatic A-cell sensitivity to hyperglycemia.

KW - Endorphin

KW - Glucagon

KW - Insulin

KW - Nalcxone

UR - http://www.scopus.com/inward/record.url?scp=0021966395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021966395&partnerID=8YFLogxK

U2 - 10.1007/BF02591089

DO - 10.1007/BF02591089

M3 - Article

VL - 22

SP - 25

EP - 31

JO - Acta Diabetologica

JF - Acta Diabetologica

SN - 0940-5429

IS - 1

ER -